See original here:
Boehringer Ingelheim and OSE Immunotherapeutics Present Phase 1 Results with First-in-Class SIRPα Inhibitor BI 765063 in Advanced Solid Tumors at...

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh